Liraglutide
- Generic Name
- Liraglutide
- Brand Names
- Saxenda, Victoza, Xultophy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 204656-20-2
- Unique Ingredient Identifier
- 839I73S42A
- Background
Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist. Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining...
- Indication
Saxenda, a formulation of liraglutide intended for weight loss, is indicated as an adjunct to diet and exercise for chronic weight management in adult patients who are obese (BMI≥30 kg/m), or who are overweight (BMI≥27 kg/m) and have at least one weight-related comorbidity. It is also indicated for chronic weight management in pediatric patients ≥12 years ol...
- Associated Conditions
- Major Adverse Cardiovascular Events, Type 2 Diabetes Mellitus
- Associated Therapies
- Chronic Weight Management therapy
Clinical Study of Liraglutide in Improving Cardiac Function for Patients With Ischemic Cardiomyopathy
- First Posted Date
- 2016-10-12
- Last Posted Date
- 2016-10-12
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT02930265
- Locations
- 🇨🇳
Chinese People's Liberation Army General Hospital, Peking, Beijing, China
Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat
- First Posted Date
- 2016-09-30
- Last Posted Date
- 2020-09-21
- Lead Sponsor
- University of Miami
- Registration Number
- NCT02920190
Effect of Liraglutide for Weight Management in Pubertal Adolescent Subjects With Obesity
- Conditions
- Interventions
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2020-04-27
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 251
- Registration Number
- NCT02918279
- Locations
- 🇸🇪
Novo Nordisk Investigational Site, Uppsala, Sweden
Low Dose Liraglutide and Metformin vs. High Dose Liraglutide Alone in Treatment of Obesity
- Conditions
- Interventions
- First Posted Date
- 2016-09-21
- Last Posted Date
- 2016-09-21
- Lead Sponsor
- University Medical Centre Ljubljana
- Target Recruit Count
- 30
- Registration Number
- NCT02909933
- Locations
- 🇸🇮
University Medical Center Ljubljana, Ljubljana, Slovenia
Study to Assess the Efficacy of Liraglutide in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2016-09-05
- Last Posted Date
- 2021-02-26
- Lead Sponsor
- Lecube, Albert, M.D.
- Target Recruit Count
- 76
- Registration Number
- NCT02889510
- Locations
- 🇪🇸
Hospital Universitari Vall d´Hebrón, Barcelona, Spain
🇪🇸Clínica Universidad de Navarra, Pamplona, Navarra, Spain
🇪🇸Hospital Universitari Arnau de Vilanova de Lleida, Lleida, Spain
HbA1c Variability in Type II Diabetes
- Conditions
- Interventions
- First Posted Date
- 2016-08-25
- Last Posted Date
- 2023-12-14
- Lead Sponsor
- Weill Cornell Medical College in Qatar
- Target Recruit Count
- 150
- Registration Number
- NCT02879409
- Locations
- 🇶🇦
Hamad Medical Corporation, Doha, Qatar
Investigating Safety, Tolerability, PK and PD for Multiple Doses of NNC9204-0530 in Combination With Liraglutide in Male and Female Subjects Being Overweight or With Obesity
- Conditions
- Interventions
- First Posted Date
- 2016-08-17
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 187
- Registration Number
- NCT02870231
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Lincoln, Nebraska, United States
Efficacy and Safety of Oral Semaglutide Versus Liraglutide and Versus Placebo in Subjects With Type 2 Diabetes Mellitus
- Conditions
- Interventions
- First Posted Date
- 2016-08-11
- Last Posted Date
- 2022-07-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 711
- Registration Number
- NCT02863419
- Locations
- 🇦🇪
Novo Nordisk Investigational Site, Umm Al Quwain, United Arab Emirates
Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period
- First Posted Date
- 2016-06-01
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 514
- Registration Number
- NCT02787551
- Locations
- 🇺🇸
Investigational Site Number 8400033, Baltimore, Maryland, United States
🇺🇸Investigational Site Number 8400079, Albany, New York, United States
🇺🇸Investigational Site Number 8400019, Columbus, Ohio, United States
Effect of Liraglutide on Clock Genes
- First Posted Date
- 2016-05-26
- Last Posted Date
- 2016-05-26
- Lead Sponsor
- Tel Aviv University
- Target Recruit Count
- 14
- Registration Number
- NCT02783196
- Locations
- 🇮🇱
Diabetes Unit E. Wolfson Hospital, Holon, Tel Aviv, Israel
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.